Biorasi Meets First Patient, First Visit Milestone for Dermatology Trial During COVID-19
Biorasi has met the First Patient, First Visit milestone for a dermatology trial across multiple sites during the COVID-19 pandemic.
Biorasi has met the First Patient, First Visit milestone for a dermatology trial across multiple sites during the COVID-19 pandemic.
Gaps in dermatological research present potentially lucrative market opportunities for pharmaceutical companies. Patients that suffer from skin conditions and diseases also benefit. Effective treatments relieve irritating, chronic, and often painful symptoms, which improves their quality of life and lifts the psychological and social burden of a visible dermatological issue.
Eczema affects more people in the United States than diabetes (10.1 vs. 9.4 million)1,2. More than […]
The success of a clinical trial depends largely on the engagement and experience of the PI. In addition to identifying and recruiting patients, site PIs and their teams conduct study procedures, complete study documentation, and retain patients for outcome assessments.
The success of any clinical trial depends on unbiased data. However, the subjective nature […]
The cosmeceuticals market continues its steady climb upward—a rise in disposable income plays a […]